Core Insights - Wall Street analysts expect CAE to report quarterly earnings of $0.14 per share, reflecting a year-over-year decline of 22.2% [1] - Revenue projections stand at $823.11 million, down 1.2% from the same quarter last year [1] - The consensus EPS estimate has been adjusted downward by 0.8% over the past 30 days, indicating a reassessment by analysts [1] Earnings Projections - Changes in earnings projections are crucial for predicting investor reactions to the stock [2] - Empirical studies show a strong correlation between earnings estimate trends and short-term stock price movements [2] Key Metrics Analysis - Analysts project 'Civil Aviation - Simulator equivalent unit (SEU)' to reach 300, up from 276 in the same quarter last year [4] - 'Civil Aviation - FFS deliveries' are estimated at 13, down from 18 in the same quarter last year [4] - The 'Civil Aviation - Utilization rate' is forecasted at 68.7%, compared to 70.0% in the same quarter last year [5] - 'Civil Aviation - FFSs in CAE's network' is expected to be 369, up from 355 in the same quarter last year [5] Stock Performance - Over the past month, CAE shares have recorded a return of -3.8%, while the Zacks S&P 500 composite has increased by 1.3% [5] - CAE holds a Zacks Rank 4 (Sell), suggesting it may underperform the overall market in the near term [5]

Core Insights - Akamai Technologies (AKAM) is expected to report quarterly earnings of $1.64 per share, a 3.1% increase year-over-year, with revenues projected at $1.04 billion, reflecting a 3.7% year-over-year growth [1] Earnings Projections - Analysts emphasize the importance of revisions to earnings projections prior to earnings releases, as these revisions are critical indicators of potential investor behavior [2] - The consensus EPS estimate for Akamai has remained unchanged over the last 30 days, indicating a collective reevaluation by analysts [1] Revenue Estimates - Analysts predict 'Revenue- Security' will reach $569.75 million, showing a year-over-year increase of 9.9% [4] - 'Revenue- Compute' is expected to be $188.02 million, reflecting a 12.7% increase from the prior-year quarter [4] - 'Revenue- Delivery' is forecasted to be $285.18 million, indicating a decline of 10.6% from the prior-year quarter [4] Stock Performance - Akamai shares have returned -5% over the past month, contrasting with the Zacks S&P 500 composite's +2.1% change [5] - With a Zacks Rank 2 (Buy), Akamai is anticipated to outperform the overall market in the near future [5]

Core Insights - Wall Street analysts anticipate PPL to report quarterly earnings of $0.46 per share, reflecting a year-over-year increase of 9.5% [1] - Expected revenues for the quarter are projected at $2.17 billion, which represents a 5.1% increase from the same quarter last year [1] - Over the past 30 days, the consensus EPS estimate has been revised downward by 3.4%, indicating a reassessment by analysts [1] Revenue Estimates - Analysts project 'Revenues- Pennsylvania Regulated' to be $760.16 million, indicating a year-over-year change of +6.2% [4] - 'Revenues- Rhode Island Regulated' is expected to reach $516.73 million, suggesting a year-over-year increase of +13.6% [4] - 'Revenues- Kentucky Regulated' is estimated to be $904.96 million, reflecting a year-over-year change of +1.1% [4] Stock Performance - PPL shares have decreased by 2% over the past month, contrasting with the Zacks S&P 500 composite's increase of +2.1% [4] - PPL holds a Zacks Rank 4 (Sell), indicating expectations of underperformance relative to the overall market in the near term [4]

Core Insights - Yum Brands (YUM) is expected to report quarterly earnings of $1.47 per share, reflecting a 7.3% increase year-over-year, with revenues projected at $1.96 billion, a 7.4% increase from the previous year [1]. Earnings Projections - The consensus EPS estimate has been revised upward by 0.8% in the last 30 days, indicating analysts' reassessment of their initial estimates [2]. - Changes in earnings projections are crucial for predicting investor reactions, as empirical studies show a strong correlation between earnings estimate trends and short-term stock price movements [3]. Revenue Estimates - Analysts forecast 'Revenues- Company sales' to reach $683.03 million, representing a 10% increase from the prior-year quarter [4]. - The consensus for 'Revenues- Franchise and property revenues' is $855.08 million, indicating a 6.4% increase year-over-year [5]. - 'Revenues- Franchise contributions for advertising and other services' are expected to be $426.27 million, reflecting a 6.3% increase from the previous year [5]. Division-Specific Metrics - The KFC Division's 'Franchise contributions for advertising and other services' are estimated at $162.06 million, a 9.5% year-over-year increase, with the number of KFC franchise and license restaurants projected at 32,384, up from 30,684 [6]. - The Taco Bell Division is projected to have a total of 8,816 restaurants, compared to 8,594 last year, with company-owned locations expected to reach 525, up from 491 [7]. - The Taco Bell franchise and license restaurants are estimated at 8,291, an increase from 8,103 in the same quarter last year [8]. - The Pizza Hut Division is expected to have 20,031 restaurants, compared to 19,927 in the same quarter last year [8]. Overall Restaurant Metrics - The total number of restaurants across all divisions is projected to be 62,097, up from 60,045 year-over-year [9]. - The number of company-owned KFC restaurants is expected to be 481, compared to 459 last year [9]. - System same-store sales for the Taco Bell Division are projected to increase by 5.1% year-over-year, up from 4.0% [9]. Stock Performance - Yum Brands shares have decreased by 8.1% over the past month, contrasting with a 2.1% increase in the Zacks S&P 500 composite, and the company holds a Zacks Rank 3 (Hold), indicating expected performance in line with the overall market [10].

Core Insights - Wall Street analysts anticipate Robinhood Markets, Inc. (HOOD) to report quarterly earnings of $0.51 per share, reflecting a year-over-year increase of 200% [1] - Expected revenues are projected to be $1.21 billion, which represents a 90.6% increase from the same quarter last year [1] Earnings Projections - Over the last 30 days, the consensus EPS estimate has been revised upward by 15.8%, indicating a collective reassessment by analysts [2] - Changes in earnings projections are crucial for predicting investor reactions to the stock [3] Revenue Estimates - Analysts expect 'Revenues- Transaction-based- Options' to be $300.17 million, a year-over-year increase of 48.6% [5] - 'Revenues- Transaction-based- Equities' is projected to reach $82.47 million, indicating a 122.9% increase from the previous year [5] - 'Revenues- Transaction-based- Cryptocurrencies' is estimated at $313.88 million, reflecting a significant year-over-year change of 414.6% [5] - The total 'Revenues- Transaction-based revenues' is expected to be $756.42 million, marking a 137.1% increase from the prior year [6] Net Interest Revenues - 'Revenues- Net interest revenues- Securities lending, net' is forecasted to be $51.10 million, a 169% increase year-over-year [7] - 'Revenues- Net interest revenues- Margin interest' is expected to reach $141.04 million, suggesting a 69.9% year-over-year change [7] - The total 'Revenues- Net interest revenues' is projected at $384.67 million, indicating a 40.4% increase from the previous year [8] Customer Metrics - Analysts project 'Funded Customers' to reach 26.85 million, up from 24.30 million in the same quarter last year [9] - 'Assets Under Custody - Total' is expected to be $306.29 billion, compared to $152.20 billion reported in the same quarter last year [9] Market Performance - Shares of Robinhood Markets have shown a return of -5.2% over the past month, contrasting with the Zacks S&P 500 composite's +2.1% change [9]

Core Insights - Analysts project ResMed (RMD) will report quarterly earnings of $2.49 per share, reflecting a 13.2% year-over-year increase, with revenues expected to reach $1.32 billion, an 8.1% increase from the same quarter last year [1]. Earnings Estimates - There has been a downward revision of 0.1% in the consensus EPS estimate over the last 30 days, indicating a collective reconsideration by analysts [2]. - Revisions to earnings projections are crucial for predicting investor behavior and are strongly linked to short-term stock price performance [3]. Revenue Projections - The consensus estimate for 'Global revenue- Total Sleep and Breathing Health' is $1.15 billion, representing an 8.1% increase year-over-year [5]. - 'Global revenue- Residential Care Software' is forecasted to reach $170.38 million, indicating an 8.7% increase from the prior year [5]. - 'Global revenue- Total Devices' is estimated at $666.36 million, reflecting a 6.5% year-over-year change [5]. Regional Revenue Insights - 'Global revenue- Total Masks and other' is projected at $484.35 million, showing a 9.6% increase from the previous year [6]. - 'U.S., Canada, and Latin America- Devices' is expected to reach $409.20 million, with a year-over-year change of 6.4% [6]. - 'U.S., Canada, and Latin America- Masks and other' is likely to be $355.76 million, indicating a 10.2% increase year-over-year [7]. - 'Combined Europe, Asia, and other markets- Total' is estimated at $385.76 million, reflecting a 7% year-over-year change [7]. - 'Combined Europe, Asia, and other markets- Devices' is projected at $257.17 million, indicating a 6.6% increase from the prior year [8]. - 'Combined Europe, Asia, and other markets- Masks and other' is expected to reach $128.59 million, suggesting a 7.9% year-over-year change [8]. - 'U.S., Canada, and Latin America- Total' is projected to be $764.96 million, reflecting an 8.2% increase year-over-year [9]. Stock Performance - Over the past month, shares of ResMed have returned -6.3%, contrasting with the Zacks S&P 500 composite's +3.8% change [9]. - ResMed currently holds a Zacks Rank 3 (Hold), indicating that its performance may align with the overall market in the near future [9].

Core Insights - FactSet Research Systems Inc. is a financial data provider with a market cap of $10.9 billion, operating globally across various regions [1] - The company is expected to announce its Q1 results by mid-December, with analysts predicting an adjusted profit of $4.39 per share, a slight increase from $4.37 in the same quarter last year [2] - For the full fiscal year 2026, adjusted EPS is projected to be $17.30, reflecting a 1.9% increase from $16.98 in 2025, with a further expected surge of 11.3% to $19.25 in fiscal 2027 [3] Stock Performance - FactSet's stock has declined by 37.2% over the past 52 weeks, significantly underperforming the Financial Select Sector SPDR Fund's 12.2% gains and the S&P 500 Index's 18.3% returns [4] - Following the release of Q4 results on September 18, the stock price dropped by 10.4% in a single trading session [5] Financial Metrics - As of the end of August, FactSet's annual subscription value (ASV) was $2.4 billion, marking a 6.7% year-over-year increase [5] - The company's revenues for the quarter rose by 6.2% year-over-year to $596.9 million, surpassing consensus estimates by 72 basis points [5] - Operating margins contracted by 200 basis points year-over-year to 33.8%, while adjusted EPS grew by 8.3% year-over-year to $4.05, falling 2.4% short of Street expectations [6] Analyst Sentiment - Analysts maintain a cautious outlook on FactSet, with a consensus "Hold" rating; among 19 analysts, there are two "Strong Buys," 10 "Holds," and seven "Strong Sells" [7] - The mean price target for the stock is $335.07, indicating a potential upside of 16.2% from current price levels [7]

Core Insights - Analysts project that Enterprise Products Partners (EPD) will report quarterly earnings of $0.67 per share, reflecting a year-over-year increase of 3.1% [1] - Revenue is expected to reach $12.59 billion, which represents an 8.6% decline from the same quarter last year [1] - The consensus EPS estimate has been revised downward by 1.7% in the past 30 days, indicating a reassessment by covering analysts [2] Financial Metrics - Analysts estimate 'NGL Pipelines & Services net - NGL fractionation volumes per day' at 1,719.13 thousand barrels, up from 1,611.00 thousand barrels a year ago [5] - The forecast for 'NGL Pipelines & Services net - Fee-based natural gas processing per day' is 7,711.24 thousand barrels, compared to 6,804.00 thousand barrels last year [5] - The consensus for 'NGL Pipelines & Services net - NGL pipeline transportation volumes per day' is 4,562.86 thousand barrels, an increase from 4,223.00 thousand barrels in the same quarter last year [6] - 'Natural Gas Pipelines & Services net - Natural gas transportation volumes per day' are estimated at 20,723 billion British thermal units, up from 19,090 billion British thermal units a year ago [7] - 'Petrochemical Services net - Butane isomerization volumes per day' are expected to be 120.61 thousand barrels, compared to 116.00 thousand barrels last year [7] - 'Petrochemical Services net - Propylene fractionation volumes per day' is projected at 113.58 thousand barrels, slightly up from 113.00 thousand barrels a year ago [8] - 'Petrochemical Services net - Octane enhancement and related plant sales volumes per day' is expected to reach 38.03 thousand barrels, compared to 37.00 thousand barrels last year [9] Operating Margins - 'NGL Pipelines & Services' gross operating margin is forecasted to be $1.37 billion, compared to $1.34 billion last year [10] - 'Crude Oil Pipelines & Services' gross operating margin is projected at $377.00 million, down from $401.00 million in the same quarter last year [11] - 'Natural Gas Pipelines & Services' gross operating margin is expected to reach $402.33 million, up from $349.00 million a year ago [11] - 'Petrochemical & Refined Products Services' gross operating margin is estimated at $343.04 million, compared to $363.00 million last year [12] Stock Performance - Over the past month, shares of Enterprise Products have returned -0.3%, while the Zacks S&P 500 composite has changed by +3.6% [12] - Currently, EPD holds a Zacks Rank 4 (Sell), indicating potential underperformance relative to the overall market in the near future [12]

Core Insights - Rithm (RITM) is expected to report quarterly earnings of $0.54 per share, unchanged from the previous year, with revenues projected at $1 billion, reflecting a 61.5% year-over-year increase [1] - The consensus EPS estimate has been adjusted downward by 0.3% over the past 30 days, indicating a reassessment by analysts [1][2] Revenue Estimates - Analysts project 'Revenues- Interest income' at $485.25 million, showing a year-over-year decline of 11.9% [4] - 'Revenues- Other revenues' are estimated to reach $30.99 million, indicating a significant decrease of 45.8% year over year [4] - 'Revenues- Asset management' is expected to be $92.22 million, reflecting a year-over-year increase of 13.8% [4] - The consensus for 'Revenues- Gain on originated residential mortgage loans, held-for-sale, net' stands at $207.43 million, suggesting a year-over-year increase of 12.3% [5] Stock Performance - Rithm shares have experienced a decline of 5% over the past month, contrasting with the Zacks S&P 500 composite's increase of 3.6% [5] - Rithm holds a Zacks Rank 2 (Buy), indicating expectations to outperform the overall market in the near future [5]

Core Insights - Alnylam Pharmaceuticals (ALNY) is expected to report quarterly earnings of $1.67 per share, reflecting a year-over-year increase of 434% [1] - Anticipated revenues are projected to reach $1.02 billion, marking a 104% increase compared to the same quarter last year [1] Earnings Projections - The consensus EPS estimate has been revised upward by 43.6% over the past 30 days, indicating a collective reassessment by analysts [2] - Changes in earnings projections are crucial for predicting investor reactions, with empirical studies showing a strong correlation between earnings estimate trends and short-term stock price movements [3] Revenue Estimates - Analysts estimate 'Revenues- Product revenues, net' at $779.02 million, representing an 85.4% year-over-year change [5] - 'Revenues- Royalty revenue' is projected at $45.94 million, indicating a 96.5% increase from the prior-year quarter [5] Product Revenue Forecasts - 'Net Product Revenue- Givlaari' is expected to be $79.33 million, reflecting an 11.7% increase year-over-year [6] - 'Revenues- Net revenues from research collaborators' are forecasted to reach $177.25 million, showing a significant change of 208.9% from the previous year [6] - 'Net Product Revenue- Oxlumo' is projected at $50.27 million, indicating a 25% increase from the prior-year quarter [6] Additional Product Revenue Insights - 'Net Product Revenue- Onpattro' is expected to decline to $46.56 million, a decrease of 7.4% from the prior-year quarter [7] - 'Net Product Revenue- Amvuttra' is forecasted to reach $602.44 million, suggesting a 133% year-over-year increase [7] - 'Net revenues from research collaborators- Regeneron Pharmaceuticals' are estimated at $17.50 million, indicating a significant decline of 53.9% [7] - 'Net revenues from research collaborators- Roche' are projected at $156.00 million, reflecting an impressive increase of 857.7% year-over-year [8] Stock Performance - Over the past month, Alnylam shares have returned +7%, outperforming the Zacks S&P 500 composite's +3.6% change [8] - Currently, ALNY holds a Zacks Rank 3 (Hold), suggesting its performance may align with the overall market in the near future [8]